Which is the first-line agent for GERD that binds irreversibly to inhibit gastric acid formation?

Which is the first-line agent for GERD that binds irreversibly to inhibit gastric acid formation?

• A. Esomeprazole
• B. Ranitidine
• C. Metoclopramide
• D. Omeprazole

Answer: (A)

The first-line agent for Gastroesophageal Reflux Disease (GERD) that binds irreversibly to inhibit gastric acid formation is a proton pump inhibitor (PPI). Esomeprazole is a specific type of PPI, which works by blocking the proton pump in the gastric parietal cells, thereby reducing the production of gastric acid. Its irreversible binding means that the effect lasts until new proton pumps are synthesized, which can take up to 24 hours. This potent suppression of acid secretion makes esomeprazole an effective choice for managing GERD and promoting healing of esophageal mucosa. In contrast, other agents listed, such as ranitidine, are H2 receptor antagonists that do not have the same irreversible mechanism and have a different pharmacologic profile. Metoclopramide is primarily a prokinetic agent that enhances gastric motility, and it does not directly inhibit acid secretion. Omeprazole, while also a PPI, is another effective first-line therapy for GERD; however, the particular distinction in the question focuses on esomeprazole as a representative of this class. Both esomeprazole and omeprazole work similarly, but the preference for esomeprazole

The first-line agent for Gastroesophageal Reflux Disease (GERD) that binds irreversibly to inhibit gastric acid formation is a proton pump inhibitor (PPI). Esomeprazole is a specific type of PPI, which works by blocking the proton pump in the gastric parietal cells, thereby reducing the production of gastric acid. Its irreversible binding means that the effect lasts until new proton pumps are synthesized, which can take up to 24 hours. This potent suppression of acid secretion makes esomeprazole an effective choice for managing GERD and promoting healing of esophageal mucosa.

In contrast, other agents listed, such as ranitidine, are H2 receptor antagonists that do not have the same irreversible mechanism and have a different pharmacologic profile. Metoclopramide is primarily a prokinetic agent that enhances gastric motility, and it does not directly inhibit acid secretion. Omeprazole, while also a PPI, is another effective first-line therapy for GERD; however, the particular distinction in the question focuses on esomeprazole as a representative of this class. Both esomeprazole and omeprazole work similarly, but the preference for esomeprazole